Theravance Biopharma (NASDAQ:TBPH) Shares Pass Above 50 Day Moving Average – Time to Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $16.23 and traded as high as $16.25. Theravance Biopharma shares last traded at $16.06, with a volume of 531,200 shares.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on TBPH shares. BTIG Research reiterated a “buy” rating and set a $21.00 price objective on shares of Theravance Biopharma in a research report on Friday, March 20th. Weiss Ratings cut shares of Theravance Biopharma from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday. Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. B. Riley Financial lifted their price objective on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. Finally, Wall Street Zen cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Theravance Biopharma has an average rating of “Moderate Buy” and a consensus price target of $21.83.

Theravance Biopharma Stock Performance

The firm’s 50 day moving average is $16.23 and its 200-day moving average is $17.57. The firm has a market cap of $827.94 million, a price-to-earnings ratio of 7.30 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The business had revenue of $17.70 million during the quarter. As a group, research analysts predict that Theravance Biopharma, Inc. will post 1.58 EPS for the current year.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. The trade was a 11.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.65% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Theravance Biopharma by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp raised its holdings in Theravance Biopharma by 4.4% in the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after acquiring an additional 45,987 shares during the period. Dimensional Fund Advisors LP raised its holdings in Theravance Biopharma by 14.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock worth $15,960,000 after acquiring an additional 124,658 shares during the period. Geode Capital Management LLC raised its holdings in Theravance Biopharma by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock worth $17,567,000 after acquiring an additional 40,734 shares during the period. Finally, Arrowstreet Capital Limited Partnership bought a new position in Theravance Biopharma in the 3rd quarter worth $10,611,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.